OptimizeRx Corp. (NASDAQ:OPRX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of OptimizeRx Corp. (NASDAQ:OPRX) have received an average rating of “Moderate Buy” from the nine brokerages that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $13.4286.

A number of analysts have recently issued reports on the company. Stifel Nicolaus cut their price objective on OptimizeRx from $17.00 to $14.00 and set a “buy” rating for the company in a research report on Wednesday, May 13th. Stephens decreased their target price on OptimizeRx from $10.00 to $7.00 and set an “equal weight” rating on the stock in a report on Wednesday, May 13th. Wall Street Zen cut OptimizeRx from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 20th. Zacks Research downgraded OptimizeRx from a “strong-buy” rating to a “hold” rating in a report on Monday, May 4th. Finally, Weiss Ratings cut shares of OptimizeRx from a “sell (d+)” rating to a “sell (d)” rating in a research report on Thursday, May 14th.

OptimizeRx Stock Performance

Shares of OPRX stock opened at $6.05 on Friday. The company has a fifty day moving average price of $5.68 and a two-hundred day moving average price of $7.09. OptimizeRx has a one year low of $4.54 and a one year high of $22.25. The stock has a market cap of $113.50 million, a P/E ratio of 17.29 and a beta of 1.08. The company has a debt-to-equity ratio of 0.16, a current ratio of 5.37 and a quick ratio of 5.37.

OptimizeRx (NASDAQ:OPRX) last released its quarterly earnings data on Tuesday, May 12th. The company reported $0.14 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.13. The company had revenue of $19.84 million for the quarter, compared to analyst estimates of $18.74 million. OptimizeRx had a net margin of 6.37% and a return on equity of 10.86%. As a group, equities analysts predict that OptimizeRx will post 0.51 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Next Century Growth Investors LLC lifted its position in OptimizeRx by 139.8% during the fourth quarter. Next Century Growth Investors LLC now owns 505,407 shares of the company’s stock worth $6,196,000 after acquiring an additional 294,688 shares during the last quarter. Manatuck Hill Partners LLC boosted its holdings in shares of OptimizeRx by 139.5% during the second quarter. Manatuck Hill Partners LLC now owns 455,000 shares of the company’s stock worth $6,142,000 after acquiring an additional 265,000 shares during the period. Kennedy Capital Management LLC grew its position in shares of OptimizeRx by 42.8% in the third quarter. Kennedy Capital Management LLC now owns 674,918 shares of the company’s stock valued at $13,836,000 after purchasing an additional 202,446 shares during the last quarter. Invesco Ltd. acquired a new position in shares of OptimizeRx in the third quarter valued at approximately $4,081,000. Finally, Segall Bryant & Hamill LLC bought a new position in shares of OptimizeRx during the first quarter worth approximately $1,185,000. Institutional investors and hedge funds own 76.47% of the company’s stock.

OptimizeRx Company Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.